Table 2.
Laboratory and clinical findings at the time of hospital admission.
| Total N = 121 | Survival N = 58 | Non survival N = 63 | p | |
|---|---|---|---|---|
| CRP (mg/L) median (IQR) | 75.2 (82.03) | 71.3 (75.8) | 85.8 (91.9) | 0.427 |
| WBC (G/L) | 8.4 ± 6.64 | 7.8 ± 6.15 | 9.1 ± 7.21 | 0.412 |
| IL-6 (pg/ml) | 82.0 (123.15) | 82.0 (103.73) | 81.45 (131.18) | 0.869 |
| Ferritin (ng/ml) | 983.5 (1224.0) | 1335.8 (1456.1) | 767.3 (1104.15) | 0.364 |
| LDH (U/l) | 447.5 (422.0) | 447.5 (369.5) | 447.0 (501.75) | 0.71 |
| Favipiravir, n (%) | 10 (8.3%) | 1 (1.7%) | 9 (14.3%) | 0.012 |
| Oxygenotherapy n (%) | ||||
| Nasal cannulas | 110 (90.9%) | 55 (94.8%) | 55 (87.3%) | 0.199 |
| HFNC | 4 (3.3%) | 0 (0%) | 4 (6.3%) | |
| CPAP | 5 (4.1%) | 2 (3.4%) | 3 (4.8%) | |
| MV | 1 (0.8%) | 0 (0.0%) | 1 (1.6%) | |
| Ambiental air | 1 (0.8%) | 1 (1.7%) | 0 (0%) | |
| Oxygenotherapy at worsening, n (%) | ||||
| Oxygen mask | 21 (17.4%) | 20 (34.5%) | 1 (1.6%) | <0.001 |
| HFNC | 26 (21.5%) | 21 (36.2%) | 5 (7.9%) | |
| CPAP | 13 (10.7%) | 8 (13.8%) | 5 (7.9%) | |
| MV | 57 (47.1%) | 5 (8.6%) | 52 (82.5%) | |
| Ambiental air | 4 (3.3%) | 4 (6.9%) | 0 (0%) | |
| Time from symptoms beginning to prior hospital admission (IQR) | 5 (4) | 5.5 (3) | 5 (5) | 0.137 |
| Time from hospital admission to TZB application (IQR) | 3 (3) | 4 (2) | 3 (2) | 0.472 |
| Days spent in ICU | 6 (5) | 8 (8) | 6 (6) | 0.086 |
| Days spent on MV | 1 (5) | 0 (0) | 3 (5) | <0.001 |
| CT severity score | 14 ± 5.9 | 16 (10) | 13 (13) | 0.855 |
CRP, C-reactive protein; WBC, White blood cells; IL-6, interleukin-6; LDH, lactate dehydrogenase; HFNC, high flow nasal cannulas; CPAP, continuous positive airway pressure; MV, mechanical ventilation; TZB, tocilizumab; ICU, intensive care unit; MV, mechanical ventilation, CT, computed tomography.